Infectious Diseases
Latest news
256 articles · 20 / page
Sutezolid Enhances Bactericidal Activity Without Class-Specific Toxicities: Insights from the PanACEA-SUDOCU-01 Trial
The Phase 2b PanACEA-SUDOCU-01 trial demonstrates that sutezolid significantly increases the bactericidal activity of a bedaquiline-delamanid-moxifloxacin regimen in pulmonary tuberculosis, notably without the neuropathy or myelosuppression
Emodepside Challenges Ivermectin’s Dominance: Phase 2a Trial Reveals Highly Effective New Treatment for Strongyloidiasis
A landmark phase 2a trial in Laos identifies emodepside as a highly effective, weight-independent treatment for Strongyloides stercoralis, achieving cure rates of 89% at a 15 mg dose, matching the current gold standard ivermectin with a rob
Functional Cure Within Reach: GSK’s Bepirovirsen Meets Primary Endpoints in Pivotal Phase III Chronic Hepatitis B Trials
GSK has announced positive Phase III results for Bepirovirsen, an antisense oligonucleotide that achieves functional cure in chronic hepatitis B patients. By targeting viral RNA and HBsAg, the drug offers a finite treatment path, potentiall
Ceftriaxone Resistance in Neisseria gonorrhoeae: Alarming Trends from the 2023 WHO EGASP Surveillance Report
The 2023 WHO EGASP study highlights a critical rise in ceftriaxone-resistant gonorrhea in Southeast Asia, with resistance reaching 20% in some regions. These findings underscore the urgent need for enhanced global surveillance and the accel
Oral Zoliflodacin Proves Non-Inferior to Standard Dual Therapy for Gonorrhoea: A Milestone in Antimicrobial Resistance Management
This phase 3 trial demonstrates that oral zoliflodacin is a viable, non-inferior alternative to ceftriaxone plus azithromycin for treating uncomplicated urogenital gonorrhoea, offering a critical solution to rising antibiotic resistance.
Beyond Child Survival: The Evolving Global Burden of Lower Respiratory Infections and Emerging Pathogens (1990-2023)
The GBD 2023 study highlights a 33.4% reduction in pediatric LRI mortality since 2010, yet 2.5 million annual deaths persist. While Streptococcus pneumoniae remains the primary pathogen, newly modeled aetiologies like non-tuberculous mycoba
Beyond the Fever: Acute Dengue Infection Linked to Significant Neurological Risks in Older Adults
A large-scale population-based study in Singapore reveals that acute dengue virus infection is associated with a nearly ten-fold increase in neurological events, including memory loss and movement disorders, particularly in older adults and
Colchicine for Long COVID: Randomized Trial Finds No Benefit in Functional Recovery or Inflammatory Resolution
A multi-center randomized clinical trial published in JAMA Internal Medicine demonstrates that colchicine, despite its potent anti-inflammatory properties, fails to improve 6-minute walk test distances or inflammatory markers in patients su
Combined Multiplex PCR and Procalcitonin Strategy Fails to Increase Antibiotic-Free Days in Critically Ill Patients with CAP: Insights from the MULTI-CAP Trial
The MULTI-CAP trial demonstrated that combining multiplex PCR and procalcitonin did not significantly increase the number of antibiotic-free days by Day 28 in ICU patients with pneumonia, although it did successfully reduce the cumulative d
Hepatitis C Eradication with Direct-Acting Antivirals: A Paradigm Shift in the Treatment of Indolent B-Cell Lymphomas
Long-term data from the BArT study and prospective observational trials demonstrate that direct-acting antivirals (DAAs) can achieve 100% viral clearance and durable hematologic responses in HCV-associated indolent lymphomas, potentially re
Precision Genomics Outperforms Empirical Approaches in Managing Drug-Resistant Helicobacter pylori
A global genomic study of Helicobacter pylori reveals that mutations in 23S rRNA and gyrA predict antibiotic resistance with 100% sensitivity, signaling the end of empirical therapy in favor of genotype-based personalized treatment.
Omadacycline Establishes Noninferiority to Moxifloxacin in Community-Acquired Bacterial Pneumonia: The OPTIC-2 Phase 3b Trial Results
The OPTIC-2 phase 3b trial confirms that omadacycline is noninferior to moxifloxacin for treating community-acquired bacterial pneumonia (CABP). This once-daily aminomethylcycline offers a robust IV-to-oral monotherapy option with a favorab
Subcutaneous Lidocaine-HP-β-CD: A Potential Disease-Modifying Breakthrough for Post-COVID Condition
A 36-week observational study demonstrates that subcutaneous lidocaine-HP-β-CD significantly improves physical and mental quality of life and reduces symptom burden in patients with post-COVID condition, offering a scalable, home-based ther
Hemodynamic vs. Neurological Phenotypes in Adult Invasive Meningococcal Disease: Insights from the Nationwide RETRO-MENINGO Study
The RETRO-MENINGO study of 654 adults reveals that hemodynamic presentations of invasive meningococcal disease carry a five-fold higher mortality risk than neurological forms. Early parenteral antibiotic administration remains the most crit
Precision Dosing in the ICU: Extended Infusions of Meropenem and Piperacillin Optimize Therapy During Renal Replacement
A large-scale multinational study reveals that meropenem and piperacillin dosing during renal replacement therapy must be tailored to RRT intensity and urine output, with extended infusions significantly improving therapeutic target attainm
Sepsis Survival in Australia and New Zealand: Analyzing Two Decades of Progress and the Recent Mortality Rebound
A large-scale study of over 300,000 ANZ ICU patients reveals that sepsis mortality plummeted from 28% to 11% between 2000 and 2020, followed by a concerning 0.9% annual increase through 2023, highlighting both clinical triumphs and emerging
Sacubitril-Valsartan Shows Biological Activity in Chagasic Heart Failure: Insights from the ANSWER-HF Trial
The ANSWER-HF trial compared sacubitril-valsartan to enalapril in patients with Chagasic heart failure. Although the primary endpoint of LVEF improvement was not met at 6 months, significant reductions in NT-proBNP and a favorable win ratio
High-Dose Influenza Vaccination Reduces Hospitalizations and Cardiovascular Events in Older Adults: Insights from the FLUNITY-HD Pooled Analysis
The FLUNITY-HD pooled analysis of over 466,000 older adults demonstrates that high-dose inactivated influenza vaccine (HD-IIV) significantly reduces hospitalizations for influenza, pneumonia, and cardiovascular causes, including a 21.3% red
Long COVID-19 in Pregnancy: Elevated Risk Amidst Mild Omicron Infection in a Boosted Vaccinated Cohort During COVID-19 Endemicity
Pregnant women show increased risk of long COVID-19 post-SARS-CoV-2 infection during Omicron predominance despite mild disease, yet incidence remains modest in a highly vaccinated cohort, highlighting vaccination’s protective role amidst em
The Role of COVID-19 Vaccination in Improving Maternal and Perinatal Outcomes: A Comprehensive Review
Vaccination against SARS-CoV-2 during pregnancy significantly lowers risks of severe maternal COVID-19, hospitalization, critical care admission, and preterm birth across variant periods, underscoring its safety and efficacy for maternal an
Browse by specialty
Open language-specific specialty feeds and department pages.